Semaglutide promotes bone marrow–derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial
In people living with either type 2 diabetes or obesity plus ASCVD risk, semaglutide increased circulating VR cell content while reducing pro-inflammatory granulocyte precursors and cytokine production. Collectively, these findings suggest that semaglutide may improve endogenous progenitor cell-mediated blood vessel repair processes.
Authors
- Arianna Z He
- C. David Mazer (ORCID: https://orcid.org/0000-0003-2566-4308)
- Hwee Teoh (ORCID: https://orcid.org/0000-0003-1036-4767)
- Ehab Bakbak (ORCID: https://orcid.org/0000-0003-4687-6553)
- Aishwarya Krishnaraj (ORCID: https://orcid.org/0000-0003-3763-478X)
- Bhavaani Lambotharan
- David A. Hess (ORCID: https://orcid.org/0000-0003-2186-3166)
- Brady Park (ORCID: https://orcid.org/0000-0001-6629-285X)
- Subodh Verma (ORCID: https://orcid.org/0000-0002-4018-8533)
- Adrian Quan (ORCID: https://orcid.org/0000-0001-8008-028X)
- Fallon Dennis (ORCID: https://orcid.org/0009-0008-7645-7599)
- Yi Pan (ORCID: https://orcid.org/0009-0003-3383-1943)
- C. Dennis
- Vaasudevan Lambotharan
- Aruna Lambotharan
- Elizabeth Misner
- Veena Thayanithy
Institutions
- Western University (CA)
- St. Michael's Hospital (CA)
- The University of Queensland (AU)
- University of Toronto (CA)
- North York General Hospital (CA)
- Canada Research Chairs (CA)
- St Michael’s Hospital (IE)
- Robarts Clinical Trials (CA)
- Health Education North West (GB)
- St Michael's Hospital (GB)
- Legacy International (US)
- St Michaels Hospital (GB)
- Unity Health Toronto
Publication Details
- Journal
- European Heart Journal
- Published
- 2025-08-20
- DOI
- https://doi.org/10.1093/eurheartj/ehaf690
- Citations
- 3
- Primary Topic
- Angiogenesis and VEGF in Cancer
- Type
- article
- Field-Weighted Citation Impact
- 2.42
Funders
- University of Toronto
- Canadian Institutes of Health Research